A Partially Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 730460 Administered as Tablets to Healthy Subjects, and a Randomised, Open-label, Single-dose, Two-way Cross-over Bioavailability Comparison of BI 730460 as Tablet With and Without Food
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2019
At a glance
- Drugs BI 730460 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 04 Feb 2019 Planned End Date changed from 15 Mar 2019 to 16 Apr 2019.
- 04 Feb 2019 Planned primary completion date changed from 15 Mar 2019 to 16 Apr 2019.
- 19 Oct 2018 Status changed from not yet recruiting to recruiting.